Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
Vincent Chung(City of Hope), John S. Kovach(Lixte (United States)), Richard S. Ungerleider(Unknown), Donald Richards(The US Oncology Network), Aaron S. Mansfield(Mayo Clinic), Fadi Braiteh(Opexa Therapeutics (United States)), Francis Johnson(Stony Brook Medicine), Henry J. Durivage(Soligenix (United States))
Cited by 126
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914